Tim A. Iseli

Tim A. Iseli

Auto-generated profile, based on publicly available information

Tim A. Iseli

Department of Surgery, Melbourne University, Royal Melbourne Hospital, Melbourne, Australia

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2009 in Otolaryngology–Head and Neck Surgery
Verified
Journal Article
Closed access
TITim A. Iseli
Tim A. Iseli
BKBrian D. Kulbersh
Brian D. Kulbersh
CIClaire E. Iseli
Claire E. Iseli
WCWilliam R. Carroll
William R. Carroll
EREben L. Rosenthal
Eben L. Rosenthal
JMJ. Scott Magnuson
J. Scott Magnuson

17 February 2015 in British Journal of Cancer
Verified
Journal Article
Open access
RYR J Young
R J Young
DUD Urban
D Urban
CAC Angel
C Angel
JCJ Corry
J Corry
BLB Lyons
B Lyons
DRDanny Rischin
Danny Rischin
Human papillomavirus (HPV) infection is a powerful prognostic biomarker in a subset of head and neck squamous cell carcinomas, specifically oropharyngeal cancers. However, the role of HPV in non-oropharyngeal sites, such as the larynx, remains unconfirmed. We evaluated a cohort of 324 laryngeal squamous cell carcinoma (LSCC) patients for the expression of p16(INK4A) (p16) protein by immunohistochemistry (IHC) and for high-risk HPV E6 and E7 mRNA transcripts by RNA in situ hybridisation (ISH). p16 expression and HPV status were correlated with clinicopathological features and outcomes. Of 307 patients assessable for p16 IHC, 20 (6.5%) were p16 positive. Females and node-positive patients were more likely to be p16 positive (P<0.05). There were no other significant clinical or demographic differences between p16-positive and -negative cases. There was no difference in overall survival (OS) between p16-positive and -negative patients with 2-year survival of 79% in each group (HR=0.83, 95% CI 0.36-1.89, P=0.65). There was no statistically significant difference in failure-free survival (FFS) with 2-year FFS of 79% and 66% for p16-positive and -negative patients, respectively (HR=0.60, 95% CI 0.26-1.36, P=0.22). Only seven cases were found to be HPV RNA ISH positive, all of which were p16 IHC positive. There was no statistically significant difference in OS between patients with HPV RNA ISH-positive tumours compared with -negative tumours with 2-year survival of 86% and 71%, respectively (HR=0.76, 95% CI 0.23-2.5, P=0.65). The 2-year FFS was 86% and 59%, respectively (HR=0.62, 95% CI 0.19-2.03, P=0.43). p16 overexpression is infrequent in LSCC and the proportion of cases with high-risk HPV transcripts is even lower. There are no statistically significant correlations between p16 IHC or HPV RNA ISH status and OS or disease outcomes.

9 December 2009 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
JKJohn P. Kostrzewa
John P. Kostrzewa
WLWilliam P. Lancaster
William P. Lancaster
TITim A. Iseli
Tim A. Iseli
RDRenee A. Desmond
Renee A. Desmond
WCWilliam R. Carroll
William R. Carroll
EREben L. Rosenthal
Eben L. Rosenthal

1 July 2014 in International Journal of Oral and Maxillofacial Surgery
Verified
Journal Article
Closed access
AYA. Yesuratnam
A. Yesuratnam
DWDavid Wiesenfeld
David Wiesenfeld
ATA. Tsui
A. Tsui
TIT.A. Iseli
T.A. Iseli
SHS.V. Hoorn
S.V. Hoorn
PPP.M. Phal
P.M. Phal

22 March 2010 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
FVFrank W. Virgin
Frank W. Virgin
TITim A. Iseli
Tim A. Iseli
CIClaire E. Iseli
Claire E. Iseli
JSJumin Sunde
Jumin Sunde
WCWilliam R. Carroll
William R. Carroll
EREben L. Rosenthal
Eben L. Rosenthal

2 July 2009 in The Journal of Laryngology & Otology
Verified
Journal Article
Closed access
PDF file
TIT A Iseli
T A Iseli
LKL H Karnell
L H Karnell
SGS M Graham
S M Graham
GFG F Funk
G F Funk
JBJohn Buatti
John Buatti
HHH T Hoffman
H T Hoffman
This study retrospectively reviewed 183 cases of adenoid cystic carcinoma treated over 40 years. The local recurrence free survival rate was 68.2 per cent at five years and 40.8 per cent at 10 years. At 10 years, local recurrence free survival was significantly worse following radiotherapy alone (0 per cent), compared with surgery alone (41.8 per cent, p = 0.004) or combined with post-operative radiotherapy (43.5 per cent, p = 0.001). Neither tumour stage three or four, perineural invasion, solid subtype nor involved margins predicted local recurrence. Treatment with radiotherapy alone resulted in worse survival than surgery alone (p = 0.002) or combined with post-operative radiotherapy (p = 0.001). Survival rates following local recurrence (n = 34) were higher following surgery (p = 0.006) but not significantly improved following radiotherapy (p = 0.139). Chemotherapy for distant metastases did not prolong survival (p = 0.747) but did result in improved eating and aesthetics scores, while decreasing overall physical health. These results indicate that surgery is preferable for primary and recurrent adenoid cystic carcinoma of the head and neck. The incidence of local recurrence following surgery and postoperative radiotherapy was similar to surgery alone cases although the latter had less adverse prognostic features. Contemporary chemotherapy may benefit quality of life but not survival in patients with distant metastases due to adenoid cystic carcinoma of the head and neck.